Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari speaks with Proactive's Stephen Gunnion about the company’s listing on Nasdaq, marking a key milestone for the biotechnology firm. Medicus raised $4 million through the IPO to fund its ongoing phase 2 proof-of-concept trial for a promising noninvasive treatment for basal cell carcinoma, the most common form of skin cancer.
The $15 billion market for skin cancer treatments reflects a significant unmet need, and Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) aims to address this with a novel combination therapy developed in collaboration with Carnegie Mellon University and the University of Pittsburgh. Bokhari emphasized that the treatment could offer a less costly, non-surgical alternative with strong aesthetic benefits. He also shared that since the company’s Toronto Stock Exchange listing last year, it has raised over $20 million, underscoring investor interest in innovative, disruptive cancer therapies.
As Medicus Pharma seeks alignment with the FDA, Bokhari expressed hopes to expedite the phase 2 trial and potentially convert it to a pivotal trial early in 2025, positioning the company to take the next big step in its development journey. "We believe we have a novel treatment that can cut costs and eliminate the need for surgical intervention," Bokhari stated. The new funds will bolster Medicus Pharma’s progress, with patient recruitment already underway.